



Tosedostat

Catalog No: tcsc0003570

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 238750-77-1
Formula: $C_{21}^{H}_{30}^{N}_{2}^{O}_{6}$
Pathway: Metabolic Enzyme/Protease
Target: Aminopeptidase
Purity / Grade: >98%
Solubility: DMSO : 25 mg/mL (61.51 mM; Need ultrasonic and warming)
Alternative Names: CHR-2797





Observed Molecular Weight:

406.47

Product Description

Tosedostat is an aminopeptidase inhibitor.

IC50 & Target: Aminopeptidase^[1]

In Vitro: Treatment of HL-60 cells with Tosedostat (CHR-2797) leads to an increase in the secretion of Stanniocalcin 2 (STC2) protein into the growth medium. Increases in SLC7A11 expression are detectable at 60 nM Tosedostat and as early as 2 h posttreatment. The IC $_{50}$ s for inhibition of proliferation by Tosedostat in U-937 and HuT 78 cell lines are 10 nM and >10 μ M, respectively. Tosedostat treatment increases expression of amino acid deprivation response (AADR) genes in U-937 cells but not in HuT 78 cells^[1]. By 24 h with 0.01 μ M Tosedostat the mean MCA production is reduced to 77.8% of the untreated control cells; similarly the MCA production is reduced to 51.3% with 1 μ M, 38.5% with 5 μ M, and 35.3% with 10 μ M Tosedostat^[2].

In Vivo: Tosedostat (CHR-2797) is active as an anticancer agent *in vivo* in rodent cancer models, and a dose-response relationship has been shown in two models. The effect of Tosedostat is less apparent when the tumor burden is higher before treatment^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!